Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Tokyo
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

4563:JP

229.0 JPY 2.0 0.87%

As of 02:00:00 ET on 05/01/2015.

Company Profile for AnGes MG Inc (4563)

AnGes MG, Inc. develops gene-therapy drugs that use Hepatocyte Growth Factor (HGF) for myocardial infarction and arteriosclerosis patients. The Company also develops nucleic acid drug (decoy oligo) for patients with asthma, allergy, and rheumatism. AnGes MG develops vectors (a carrier used to introduce a foreign gene into a host cell) which help study and analyze genetic functions.

Contact Information

AnGes MG Inc

7-7-15 Saitoasagi
Ibaraki
Osaka, 567-0085
Japan
Phone: 81-72-643-3590

Key Executives for AnGes MG Inc (4563)

Ei YamadaPresident/CEO

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisements
Advertisement
sec ||= nil